158 related articles for article (PubMed ID: 36405594)
1. Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion and cellular immunity recovery without inducing cytokine release syndrome.
Jiang Y; Feng D; Wang C; Zhang Y; Zhao C; Li S; Qin Y; Chang AH; Zhu J
Front Med (Lausanne); 2022; 9():1042501. PubMed ID: 36405594
[TBL] [Abstract][Full Text] [Related]
2. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
Ma S; Li H; Zhou D; Zhang X; Shi M; Cao J; Qi Y; Xia J; Liu Y; Wang X; Li D; Sang W; Yan Z; Zhu F; Sun H; Cheng H; Zheng J; Xu K; Li Z; Qi K; Wang Y
Cytotherapy; 2023 Jun; 25(6):653-658. PubMed ID: 36907717
[TBL] [Abstract][Full Text] [Related]
3. Early granulocyte colony stimulating factor administration increases the risk of cytokine release syndrome in acute lymphoblastic leukemia patients receiving anti-CD19 chimeric antigen receptor T-cell therapy.
Cao M; Han S; Qiu Y; Zhou L; Su Y; Tu S; Li Y
Hematol Oncol; 2023 Dec; 41(5):933-941. PubMed ID: 37259483
[TBL] [Abstract][Full Text] [Related]
4. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
Sterner RM; Sakemura R; Cox MJ; Yang N; Khadka RH; Forsman CL; Hansen MJ; Jin F; Ayasoufi K; Hefazi M; Schick KJ; Walters DK; Ahmed O; Chappell D; Sahmoud T; Durrant C; Nevala WK; Patnaik MM; Pease LR; Hedin KE; Kay NE; Johnson AJ; Kenderian SS
Blood; 2019 Feb; 133(7):697-709. PubMed ID: 30463995
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex.
Levine JD; Allan JD; Tessitore JH; Falcone N; Galasso F; Israel RJ; Groopman JE
Blood; 1991 Dec; 78(12):3148-54. PubMed ID: 1742482
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF.
Weisdorf DJ; Verfaillie CM; Davies SM; Filipovich AH; Wagner JE; Miller JS; Burroughs J; Ramsay NK; Kersey JH; McGlave PB
Blood; 1995 Jun; 85(12):3452-6. PubMed ID: 7540062
[TBL] [Abstract][Full Text] [Related]
7. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma.
Miller KC; Johnson PC; Abramson JS; Soumerai JD; Yee AJ; Branagan AR; O'Donnell EK; Saucier A; Jacobson CA; Frigault MJ; Raje NS
Blood Cancer J; 2022 Nov; 12(10):146. PubMed ID: 36316312
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP
Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
[TBL] [Abstract][Full Text] [Related]
11. Cell-Based Models of 'Cytokine Release Syndrome' Endorse CD40L and Granulocyte-Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy.
Dibas A; Rhiel M; Patel VB; Andrieux G; Boerries M; Cornu TI; Alzubi J; Cathomen T
Cells; 2023 Nov; 12(21):. PubMed ID: 37947658
[TBL] [Abstract][Full Text] [Related]
12. Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells.
Sterner RM; Cox MJ; Sakemura R; Kenderian SS
J Vis Exp; 2019 Jul; (149):. PubMed ID: 31380838
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys.
Neelis KJ; Hartong SC; Egeland T; Thomas GR; Eaton DL; Wagemaker G
Blood; 1997 Oct; 90(7):2565-73. PubMed ID: 9326222
[TBL] [Abstract][Full Text] [Related]
14. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
Peters WP; Rosner G; Ross M; Vredenburgh J; Meisenberg B; Gilbert C; Kurtzberg J
Blood; 1993 Apr; 81(7):1709-19. PubMed ID: 7681699
[TBL] [Abstract][Full Text] [Related]
16. Myelopoietin, a chimeric agonist of human interleukin 3 and granulocyte colony-stimulating factor receptors, mobilizes CD34+ cells that rapidly engraft lethally x-irradiated nonhuman primates.
MacVittie TJ; Farese AM; Davis TA; Lind LB; McKearn JP
Exp Hematol; 1999 Oct; 27(10):1557-68. PubMed ID: 10517498
[TBL] [Abstract][Full Text] [Related]
17. RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines.
Shang S; Chen Y; Yang X; Yang Y; Wang W; Wang Y
Invest New Drugs; 2023 Apr; 41(2):220-225. PubMed ID: 36988829
[TBL] [Abstract][Full Text] [Related]
18. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators.
Sachdeva M; Duchateau P; Depil S; Poirot L; Valton J
J Biol Chem; 2019 Apr; 294(14):5430-5437. PubMed ID: 30804212
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human granulocyte-macrophage colony-stimulating factor in septic neutropenic pediatric cancer patients: detection of circulating hematopoietic precursor cells correlates with rapid granulocyte recovery.
Fink FM; Maurer-Dengg K; Fritsch G; Mann G; Zoubek A; Falk M; Gadner H
Med Pediatr Oncol; 1995 Nov; 25(5):365-71. PubMed ID: 7545780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
